semaglutide microneedle patch (DWRX5003)
/ Daewoong Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 17, 2026
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Apr 2026 ➔ Oct 2026
Enrollment open • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
April 21, 2026
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.
New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
October 01, 2025
Daewoong pushes semaglutide into patches with phase 1 trial launch in Korea
(Korea Biomedical Review)
- "The first-in-human trial will assess safety and pharmacokinetics in healthy adults and measure relative bioavailability against Novo Nordisk’s injectables Ozempic and Wegovy."
New P1 trial • Obesity
1 to 3
Of
3
Go to page
1